The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from GlobeNewswire (a Nasdaq OMX company)

Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2012 Investor Conference Call

Wednesday, February 27, 2013

Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2012 Investor Conference Call06:14 EST Wednesday, February 27, 2013CAMBRIDGE, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2012 Investor Conference Call and webcast at 10 a.m., Eastern time, on Thursday, March 14. The call will cover an update on Merrimack's progress as well as a summary of fourth quarter financials. A press release detailing the information to be discussed on the call will be issued on Thursday, March 14 prior to the call. Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 15777363. Slides accompanying the call and a listen-only webcast of the call can be accessed in the Investor Relations section of Merrimack's website, http://investors.merrimackpharma.com, and a replay of the call will be archived there.  About Merrimack Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development. Forward-looking statements Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.CONTACT: Investor & Media Contact: Kathleen Petrozzelli Gallagher Corporate Communications, Merrimack 617-441-1043 kgallagher@merrimackpharma.com